Functionalized pyrazoles and pyrazolo[3,4-d]pyridazinones: Synthesis and evaluation of their phosphodiesterase 4 inhibitory activity

Bioorg Med Chem. 2010 May 15;18(10):3506-17. doi: 10.1016/j.bmc.2010.03.066. Epub 2010 Mar 31.

Abstract

A series of pyrazoles and pyrazolo[3,4-d]pyridazinones were synthesized and evaluated for their PDE4 inhibitory activity. All the pyrazoles were found devoid of activity, whereas some of the novel pyrazolo[3,4-d]pyridazinones showed good activity as PDE4 inhibitors. The most potent compounds in this series showed an IC(50) in the nanomolar range. The ability to inhibit TNF-alpha release in human PBMCs was determined for two representative compounds, finding values in the sub-micromolar range. SARs studies demonstrated that the best arranged groups around the heterocyclic core are 2-chloro-, 2-methyl- and 3-nitrophenyl at position 2, an ethyl ester at position 4 and a small alkyl group at position 6. Molecular modeling studies performed on a representative compound allowed to define its binding mode to the PDE4B isoform.

MeSH terms

  • Humans
  • Inhibitory Concentration 50
  • Male
  • Models, Molecular
  • Molecular Structure
  • Phosphodiesterase 4 Inhibitors*
  • Phosphodiesterase Inhibitors / chemical synthesis
  • Phosphodiesterase Inhibitors / pharmacology
  • Pyrazoles / chemical synthesis
  • Pyrazoles / pharmacology*
  • Pyridazines / chemical synthesis
  • Pyridazines / pharmacology*
  • Structure-Activity Relationship
  • Substrate Specificity
  • Tumor Necrosis Factor-alpha / drug effects
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Phosphodiesterase 4 Inhibitors
  • Phosphodiesterase Inhibitors
  • Pyrazoles
  • Pyridazines
  • Tumor Necrosis Factor-alpha